Procaps Group S.A. (PROC)
Market Cap | 327.21M |
Revenue (ttm) | 414.10M |
Net Income (ttm) | 52.20M |
Shares Out | 112.82M |
EPS (ttm) | 0.52 |
PE Ratio | 5.58 |
Forward PE | 31.59 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,090 |
Open | 2.870 |
Previous Close | 2.700 |
Day's Range | 2.870 - 2.900 |
52-Week Range | 1.950 - 5.380 |
Beta | 0.13 |
Analysts | Hold |
Price Target | 4.50 (+55.17%) |
Earnings Date | May 10, 2024 |
About PROC
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PROC stock is "Hold" and the 12-month stock price forecast is $4.5.
News
Procaps Group – Notice to Shareholders
MIAMI & BARRANQUILLA, Colombia.--(BUSINESS WIRE)--Dear Shareholders, We became aware on Saturday, January 13, 2024, that the online voting instructions related to the upcoming General Meeting of Share...
Procaps Group Reports Third Quarter 2023 Results
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Reports Third Quarter 2023 Results.
Statement from the Board of Directors of Procaps Group
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Statement from the Board of Directors of Procaps Group.
Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America
Agreement Combines Procaps Oral Delivery System Technology and Manufacturing with Genomma's Strategic Marketing and Distribution Footprint BARRANQUILLA, Colombia and MEXICO CITY and MIAMI , Nov. 29, 2...
Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024.
Procaps Group Update on Third Quarter Results
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Update on Third Quarter Results.
Procaps Group to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group to Report Third Quarter and Nine Months Results on Tuesday November 14 and Host Conference Call on Thursday November 16 at 10:30a.m. ET.
Procaps Group Wins First Place in Ranking of Innovative Companies in the Pharma Sector in Colombia
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Wins First Place in Ranking of Innovative Companies in the Pharma Sector in Colombia.
Procaps Group to Participate at CPHI Barcelona 2023
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today that it will participa...
Procaps Group to Host Webinar on Colombian Pharma Market
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group to Host Webinar on Colombian Pharma Market Tuesday, October 10, 2023 at 10:00 a.m. Eastern Time.
Procaps Group to Participate at BTG 2023 LatAm CEO Conference and Roth 2023 Healthcare Opportunities Conference in October
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group to Participate at BTG 2023 LatAm CEO Conference and Roth 2023 Healthcare Opportunities Conference in October.
Procaps Group Announces the Expansion of its Oncology Portfolio
MIAMI & BARRANQUILLA, Columbia--(BUSINESS WIRE)--Procaps Group Announces the Expansion of its Oncology Portfolio.
Procaps Group Reports Second Quarter 2023 Results
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Reports Second Quarter 2023 Results.
Procaps Group to Report Second Quarter and First Half 2023 Results and Host Conference Call on Tuesday
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group to Report Second Quarter and First Half 2023 Results and Host Conference Call on Tuesday.
Procaps Group Publishes White Paper on Innovative Gummy Technology
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Publishes White Paper on Innovative Gummy Technology.
Procaps Group Reports First Quarter 2023 Results
Constant Currency Net Revenues Increased 10% Quarter-over-Quarter in 1Q23, and 22% increase in Adjusted EBITDA, With Strong Demand of RX and Softgel Portfolios, Offset by Clinical Specialty Covid Port...
Procaps Group Reports Fourth Quarter and Full Year 2022 Results
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Reports Fourth Quarter and Full Year 2022 Results.
Financial Results and Business Update Conference Call to be Held May 2023 in Conjunction with 20-F Filing
MIAMI and BARRANQUILLA, Colombia, May 01, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerat...
Procaps Issues Shareholder Letter and Provides Preliminary Fiscal Year 2022 Financial Results and 2023 Guidance
Reports Preliminary Financial Estimates for Net Revenue and Adjusted EBITDA for Full Year 2022
Procaps Announces Key Changes to the Board of Directors
International Corporate Executive and Attorney Alberto Eguiguren Correa Appointed to Board of Directors International Corporate Executive and Attorney Alberto Eguiguren Correa Appointed to Board of Di...
Procaps Group Announces Termination of Acquisition Agreement with Grupo Somar
Company to Provide 2023 Value Creation Plan at J.P. Morgan Healthcare Conference Company to Provide 2023 Value Creation Plan at J.P. Morgan Healthcare Conference
Procaps to Present at 2023 Annual J.P. Morgan Healthcare Conference
MIAMI and BARRANQUILLA, Colombia, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomera...
Update on Proposed Acquisition of Grupo Somar
MIAMI and BARRANQUILLA, Colo., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate,...
Procaps Group Reports Third Quarter and Nine Months 2022 Results
Constant currency Net Revenues Increased by 15% year-over-year in the 9M22 and by 11% in the 3Q22, signaling a strong demand across our businesses Constant currency Net Revenues Increased by 15% year-...
Procaps Group to Report Third Quarter and Nine Months of 2022 on November 14, 2022
MIAMI and BARRANQUILLA, Colombia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that it e...